Clinical data | |
---|---|
Pronunciation | ['hɛpərɪn] HEP-ə-rin |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration |
IV, SQ |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Erratic |
Metabolism | Liver |
Biological half-life | 1.5 hours |
Excretion | Urine |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.029.698 |
Chemical and physical data | |
Formula | C12H19NO20S3 |
Molar mass | 12000–15000 g/mol |
|
|
(what is this?) |
Heparin, also known as unfractionated heparin (UFH), is medication which is used as a blood thinner. Specifically it is used to treat and prevent deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. It is also used in the treatment of heart attacks and unstable angina. It is given by injection into a vein. Other uses include inside test tubes and kidney dialysis machines.
Common side effects include bleeding, pain at the injection site, and low blood platelets. Serious side effects include heparin induced thrombocytopenia. Greater care is needed in those with poor kidney function. Heparin appears to be relatively safe for use during pregnancy and breastfeeding. Heparin is a naturally occurring glycosaminoglycan.
The discovery of heparin was announced in 1916. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world, when used for prevention, is about 9.63 to 37.95 USD per month. In the United States it costs about 25 to 50 USD per month. A fractionated version of heparin, known as low molecular weight heparin is also available.